Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Receivables - Other: 2019-2025

Historic Receivables - Other for Legend Biotech (LEGN) over the last 4 years, with Sep 2025 value amounting to $1.2 million.

  • Legend Biotech's Receivables - Other fell 38.71% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 38.71%. This contributed to the annual value of $780,000 for FY2024, which is 1.27% down from last year.
  • According to the latest figures from Q3 2025, Legend Biotech's Receivables - Other is $1.2 million, which was up 11.14% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Receivables - Other peaked at $50.0 million during Q4 2021, and registered a low of $46,000 during Q2 2021.
  • Over the past 3 years, Legend Biotech's median Receivables - Other value was $1.1 million (recorded in 2024), while the average stood at $10.5 million.
  • In the last 5 years, Legend Biotech's Receivables - Other soared by 7,977.54% in 2021 and then plummeted by 98.10% in 2022.
  • Over the past 5 years, Legend Biotech's Receivables - Other (Quarterly) stood at $50.0 million in 2021, then tumbled by 98.10% to $948,000 in 2022, then fell by 16.67% to $790,000 in 2023, then declined by 1.27% to $780,000 in 2024, then slumped by 38.71% to $1.2 million in 2025.
  • Its Receivables - Other stands at $1.2 million for Q3 2025, versus $1.1 million for Q2 2025 and $954,000 for Q1 2025.